Search results: (10000)
News Rebound effect after denosumab discontinuation in a patient with lung cancer
The case study of a patient with metastatic lung cancer describes the emergence of vertebral fractures following the discontinuation of denosumab. This antiresorptive treatment was halted prophylactically to reduce the risk of osteonecrosis in connection with a planned dental procedure. Fifteen months after receiving the last dose of denosumab, the patient experienced atraumatic compression fractures of the spine requiring kyphoplasty to alleviate symptoms. Other causes of the fractures were ruled out.
News Prevention of Symptomatic Skeletal Events in Postmenopausal Women with Advanced ER-Positive Breast Cancer
Advanced breast cancer with the presence of estrogen receptors is one of the most common cancers worldwide. Hormonal treatment for this malignancy is highly effective, but it is accompanied by risks such as symptomatic skeletal events (SSE). However, this undesired anti-estrogen effect can be prevented by administering appropriate antiresorptive drugs. A retrospective study by Hong Kong researchers focused on the effectiveness of these drugs in clinical practice.
News Contact Dermatitis in Patients with Venous Ulcers – and How to Prevent It?
The prevalence of chronic wounds increases with the rising average age, and for example, venous ulcers affect up to 2% of the global population. Materials used for wound coverage, however, present a risk for the development of contact dermatitis of allergic or irritant origin. The topic of contact dermatitis in patients with venous ulcers is covered in a review article published in the International Journal of Women’s Dermatology.
News Effectiveness of Compression Therapy in Patients with Leg Ulcers
Up to 2% of the population suffers from leg ulcers. The standard treatment for ulcers of venous etiology is compression. The following French study, whose results were recently published in the International Journal of Angiology, examined its effectiveness and safety in patients with mixed (arteriovenous) etiology ulcers.
News Rurioctocog Alfa Pegol vs. Non-factor Therapy – Report from Real Clinical Practice
The standard treatment for hemophilia A is the prophylactic administration of coagulation factor VIII (FVIII) concentrate. Recently, some hemophiliacs have also been switched to prophylaxis with so-called non-factor therapy, specifically emicizumab. A recently published report from the USA shows a comparison of these two modalities in real clinical practice.
News The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
We summarize the results of a clinical study on the effect of probiotics containing Limosilactobacillus reuteri on the improvement of gingivitis in patients with diabetes. It has been proven that the supplementary administration of L. reuteri statistically significantly improves gum health and helps to suppress gingival inflammation.
News The role of the physiotherapist in hemophilia care is expanding and irreplaceable − what it entails and how it changes with treatment advances?
In the team cooperation in caring for patients with hemophilia, the physiotherapist plays a very important role, which is expanding with today's comprehensive approach to treating this condition. The reason is that even in the era of modern treatment availability, many hemophilia patients have various musculoskeletal complications. A team of authors, preferentially physiotherapists, recently published a paper pondering whether the advent of new drugs will also change the position of physiotherapy in the care of patients with hemophilia.
News Impact of the combination of bevacizumab with erlotinib in patients with NSCLC and EGFR mutation on overall survival and time to disease progression
Dual inhibition of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) can delay resistance to chemotherapy in patients with advanced-stage non-small cell lung cancer (NSCLC). The study presented below examined the efficacy and safety of the erlotinib + bevacizumab combination compared to erlotinib monotherapy in these patients.
News Efficacy and Safety of Levodopa/Entacapone/Carbidopa Combination in the Treatment of Advanced Parkinson's Disease – Prospective ELEGANCE Study
Therapy for advanced Parkinson's disease (PD) with a triple combination of levodopa/entacapone/carbidopa in the form of intestinal gel (LECIG) was first introduced to the Swedish market in 2018. The German team behind the ELEGANCE study aimed to gather available data and analyze the efficacy and safety of this modality in the long-term treatment of PD.
News First Experiences with the Combination of Levodopa/Entacapone/Carbidopa in Intestinal Gel from the Perspective of Patients with Parkinson's Disease
The work presented at the 8th Congress of the European Academy of Neurology (EAN) in Vienna in June 2022 summarizes the first experiences with the use of intestinal gel combining the active ingredients levodopa/entacapone/carbidopa in patients with Parkinson’s disease (PD) in clinical practice in Austria.
News ESC 2022: Evidence of SGLT2i Effectiveness in HFrEF Treatment is Growing: How to Integrate Them into Routine Practice?
Although the need for pharmacotherapeutic options for patients with heart failure with reduced left ventricular ejection fraction (HFrEF) is essential, challenges in implementing this medication according to guidelines persist. This issue was also discussed at a symposium held as part of this year's European Society of Cardiology Congress (ESC 2022).
News ESC 2022: SGLT2 Inhibitors as Hope for HFpEF: How to Implement Them in Practice?
Patients with heart failure (HF) can significantly benefit from the inclusion of sodium-glucose co-transporter 2 inhibitors (SGLT2i, i.e., gliflozins) in their treatment strategy according to current findings. This also applies to patients with preserved left ventricular ejection fraction (HFpEF). At the ESC 2022 congress, useful information for practical applications was presented in addition to study data. For illustration, we bring a case study from a German practice.
News Protective Effect of SGLT2 Inhibitors on Heart Muscle Function - Findings from a Recent Meta-analysis
Sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) primarily offer the ability to achieve very good glycemic control with a low risk of hypoglycemia. Their undeniable advantage, however, is their cardiovascular safety and renoprotective effect. The impact of gliflozins on heart functions has already been the subject of many studies, the findings of which are summarized in a recently published meta-analysis.
News Alpha-1 Antitrypsin Deficiency and Lung Disease in Patients with Primary Immunodeficiencies
Alpha-1 antitrypsin deficiency (AATD) plays a significant role in the pathogenesis of pulmonary emphysema, chronic obstructive pulmonary disease (COPD), and bronchiectasis. However, its deficiency may also play a role in other lung diseases.
News Can identifying alpha-1 antitrypsin deficiency before liver transplantation extend survival?
Alpha-1 antitrypsin deficiency (AATD) can manifest (among other things) as liver cirrhosis. The study presented below examined the survival of patients diagnosed with AATD before and after liver transplantation.